EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Treatment of Hyperthyroidism in Graves' Disease Complicated by Thyroid Eye Disease

Luigi Bartalena iD, Terry J Smith iD

The Journal of Clinical Endocrinology & Metabolism · 17.03.2025 · 110 (4) · 922-930

DOI: 10.1210/clinem/dgaf009 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 09.01.2025. Verfasst von Luigi Bartalena und 1 weiteren Autor:innen. Beteiligte Einrichtung: The School of Medicine, University of Insubria, Varese 21100, Italy. Hauptthemen laut MEDLINE: Graves Ophthalmopathy, Graves Disease, Hyperthyroidism, Antithyroid Agents. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 94 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thyroid eye disease (TED) is the most consequential extrathyroidal manifestation or complication of Graves' disease (GD). Treatment of hyperthyroidism in GD complicated by TED is challenging. Antithyroid drugs (ATDs) and thyroidectomy do not change the natural course of TED, while radioactive iodine (RAI) is associated with a small but well-documented risk of TED de novo occurrence or its progression/worsening. In the presence of mild TED, any treatment for hyperthyroidism can be used, but should RAI treatment be selected, steroid prophylaxis (short course of low-dose prednisone) is strongly recommended if TED is of recent onset and/or risk factors for progression exist. In moderate to severe and active TED, ATDs are the preferred treatment, but thyroidectomy is a valid option. RAI ablation is generally avoided; it might be used when the clinical situation calls for it, but with extreme caution, if an aggressive treatment for TED with high-dose glucocorticoids (with or without orbital radiotherapy) is administered concomitantly. In moderate to severe and inactive TED, all 3 treatments for hyperthyroidism are acceptable, and steroid prophylaxis in RAI-treated patients should be given when risk factors for TED progression are identified. Management of sight-threatening TED represents the absolute priority, and hyperthyroidism should be controlled with ATDs until TED has been controlled. Search Strategies Current guidelines, original articles, clinical trials, systematic reviews, and meta-analyses up to June 2024 were searched using the following terms: “Graves' disease,” “management of Graves' disease,” “antithyroid drugs,” “radioactive iodine,” “thyroidectomy,” “thyroid eye disease,” “Graves' orbitopathy or ophthalmopathy.”

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graves OphthalmopathyGraves DiseaseHyperthyroidismAntithyroid AgentsHumansIodine RadioisotopesThyroidectomy

Stichwörter der Autor:innen

Graves' diseaseGraves' orbitopathyantithyroid drugsradioactive iodinethyroid eye diseasethyroidectomy

Substanzen

Antithyroid AgentsIodine Radioisotopes

Autor:innen und Institutionen

  • The School of Medicine, University of Insubria, Varese 21100, Italy.
  • Department of Ophthalmology and Visual Sciences and Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48105, USA.

ORCID-Profile: Luigi Bartalena, Terry J Smith

Zitieren

APA

Bartalena, L., & Smith, T. J. (2025). Treatment of Hyperthyroidism in Graves' Disease Complicated by Thyroid Eye Disease. The Journal of Clinical Endocrinology & Metabolism, 110(4), 922-930. https://doi.org/10.1210/clinem/dgaf009

Vancouver

Bartalena L, Smith TJ. Treatment of Hyperthyroidism in Graves' Disease Complicated by Thyroid Eye Disease. The Journal of Clinical Endocrinology & Metabolism. 2025;110(4):922-930. doi:10.1210/clinem/dgaf009

BibTeX
@article{Bartalena2025,
  author = {Bartalena, Luigi and Smith, Terry J},
  title = {Treatment of Hyperthyroidism in Graves' Disease Complicated by Thyroid Eye Disease},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  volume = {110},
  number = {4},
  pages = {922--930},
  doi = {10.1210/clinem/dgaf009}
}
Kostenlos starten →